# Celgene Corporation clinical trials: 52 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 52 trials with Celgene Corporation as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Celgene Corporation: 52 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/celgene-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 52
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 52, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 1, 2016 | NCT02820935 | Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects | Celgene Corporation | Phase 1 | Completed | Pharmacokinetics | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02820935) |
| January 13, 2016 | NCT02655159 | Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice | Celgene Corporation | Observational | Terminated | Breast Neoplasms | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02655159) |
| December 22, 2014 | NCT02321644 | Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study | Celgene Corporation | Phase 1 | Completed | Healthy Subjects | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02321644) |
| April 10, 2014 | NCT02110420 | First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001 | Celgene Corporation | Phase 1 | Completed | Healthy Volunteers | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02110420) |
| January 13, 2014 | NCT02034773 | 3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability... | Celgene Corporation | Phase 1 | Completed | Healthy Volunteers | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02034773) |
| December 13, 2013 | NCT02011113 | Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma | Celgene Corporation | Phase 2 | Completed | Multiple Myeloma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02011113) |
| August 30, 2013 | NCT01933061 | Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic... | Celgene Corporation | Phase 2 | Withdrawn | Metastatic Melanoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01933061) |
| July 25, 2013 | NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | Celgene Corporation | Phase 1 | Terminated | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin... | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01908387) |
| December 7, 2012 | NCT01744626 | Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Celgene Corporation | Phase 1 | Completed | Leukemia Lymphocytic Chronic B-Cell | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01744626) |
| December 15, 2009 | NCT01032291 | A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal... | Celgene Corporation | Phase 2 | Terminated | Colorectal Cancer | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01032291) |
| June 1, 2009 | NCT00910858 | A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic... | Celgene Corporation | Phase 1/2 | Completed | Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00910858) |
| February 2, 2009 | NCT00833833 | MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple... | Celgene Corporation | Phase 1/2 | Completed | Multiple Myeloma | 259 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00833833) |
| January 17, 2008 | NCT00596999 | A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched... | Celgene Corporation | Observational | Unknown | Hematologic Malignancies | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00596999) |
| August 20, 2007 | NCT00518284 | Prevention of Restenosis Following Revascularization | Celgene Corporation | Phase 2 | Terminated | Vascular Disease, Peripheral | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00518284) |
| May 25, 2007 | NCT00478777 | A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With... | Celgene Corporation | Phase 3 | Completed | Relapsed or Refractory Multiple Myeloma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00478777) |
| May 16, 2007 | NCT00474188 | A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Celgene Corporation | Phase 2 | Terminated | Diffuse Large B-cell Lymphoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00474188) |
| March 12, 2007 | NCT00446433 | A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease | Celgene Corporation | Phase 2 | Completed | Crohn's Disease | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00446433) |
| January 11, 2007 | NCT00420849 | A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | Celgene Corporation | Phase 3 | Completed | Multiple Myeloma | 587 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00420849) |
| November 30, 2006 | NCT00405756 | A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. | Celgene Corporation | Phase 3 | Completed | Newly Diagnosed Multiple Myeloma | 459 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00405756) |
| September 27, 2006 | NCT00380835 | Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer | Celgene Corporation | Phase 2 | Withdrawn | Metastatic Breast Cancer | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00380835) |
| April 27, 2006 | NCT00319969 | Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. | Celgene Corporation | Phase 2 | Completed | Small Cell Lung Cancer | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00319969) |
| September 16, 2005 | NCT00179751 | A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas | Celgene Corporation | Phase 1/2 | Terminated | Pancreatic Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00179751) |
| September 16, 2005 | NCT00179738 | A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in... | Celgene Corporation | Phase 2 | Terminated | Prostate Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00179738) |
| September 16, 2005 | NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide... | Celgene Corporation | Phase 1/2 | Terminated | Ovarian Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00179725) |
| September 16, 2005 | NCT00179712 | Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | Celgene Corporation | Phase 1/2 | Completed | Ovarian Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00179712) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 1/2 | 7 |
| Phase 2 | 20 |
| Phase 2/3 | 2 |
| Phase 3 | 8 |
| Not applicable | 1 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 37 |
| Terminated | 12 |
| Withdrawn | 2 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Myeloma | 9 |
| Myelodysplastic Syndromes | 5 |
| Breast Neoplasms | 5 |
| Neoplasm Metastasis | 4 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Recurrence | 3 |
| Lymphoma, Non-Hodgkin | 3 |
| Prostatic Neoplasms | 2 |
| Melanoma | 2 |
| Ovarian Neoplasms | 2 |
| Leukemia | 2 |
| Reflex Sympathetic Dystrophy | 2 |
| Pain | 2 |
| Complex Regional Pain Syndromes | 2 |
| Neoplasms | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Hematologic Neoplasms | 2 |
| HIV Infections | 2 |
| HIV Wasting Syndrome | 2 |
| Acquired Immunodeficiency Syndrome | 2 |
| Cachexia | 2 |
| Colorectal Neoplasms | 2 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Leukemia, Myeloid | 1 |
| Small Cell Lung Carcinoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Gluten free restaurants in the United States](https://specstream.ai/data/businesses/gluten-free-restaurants/united-states)
- [Auto insurance agencies in the United States](https://specstream.ai/data/businesses/auto-insurance-agencies/united-states)
- [Patent law firms in the United States](https://specstream.ai/data/businesses/patent-law-firms/united-states)
- [E-commerce services in the United States](https://specstream.ai/data/businesses/e-commerce-services/united-states)
- [Truck repair shops in the United States](https://specstream.ai/data/businesses/truck-repair-shops/united-states)
- [Law schools in the United States](https://specstream.ai/data/businesses/law-schools/united-states)
